SWOG clinical trial number
S0701

A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Gastric Cancer Prevention
Activated
06/16/2009
Closed
06/30/2010
Participants
Limited: Institutions Listed on the Title Page

Research committees

Prevention & Epidemiology

Treatment

clarithromycin metronidazole bismuth subsalicylate / subcitrate tetracycline lansoprazole amoxicillin

Eligibility Criteria Expand/Collapse

Step 1: Participant must be between 21-65 years of age; be the only member from their household participating; no known allergies to study drugs; no known medical conditions other than H. pylori that requires antibiotic therapy; no known medical conditions that may limit life expectancy;must discontinue use or alcohol, antacids, PPIs; no antibiotics within last 30 days prior to registration; willing to return for follow-up visits; allow submission of blood. Female participants must not be pregnant or nursing. Step 2 critieria: Positive UBT test; negative pregnancy test if applicable.

Publication Information Expand/Collapse

2013

Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities

D Morgan;J Torres;R Sexton;R Herrero;E Salazar-Martinez;ER Greenberg;LE Bravo;RL Dominquez;C Ferreccio;EC Lazcano-Ponce;MM Meza-Montenegro;EM Pena;R Pena;P Correa;ME Martinez;WD Chey;M Valdivieso;GL Anderson;GE Goodman;JJ Crowley;LH Baker Journal of the American Medical Association, 309(6):578-586;

PMid: PMID23403682 | PMC number: PMC3697935

Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG trial S0701)

C Porras;J Nodora;R Sexton;R Ferreccio;S Jimenez;RL Dominguez;MP Cook;GL Anderson;DR Morgan;LH Baker;ER Greenberg;R Herrero Cancer Causes and Control 24(2):209-215;

PMid: PMID23263777 | PMC number: PMC3645498

2012

Risk factors for H. pylori recurrence one year after eradication treatment in a population randomized trial (SWOG S0701) in seven Latin American sites

DR Morgan;J Torres;GL Anderson;ER Greenberg;E Salazar-Martinez;R Dominguez;C Ferreccio;LE Bravo;R Pena;R Herrero;ME Martinez;P Correa;M Valdivieso;GL Anderson;WD Chey;JJ Crowley;LH Baker Gastroenterology Vol. 142, Issue 5, Suppl 1, p. S-478-S-479, abst. Su1673; Digestive Disease Week Annual Meeting, poster;

Rome III criteria-based prevalence of dyspepsia symptoms in general populations in six countries in Latin America (SWOG trial S0701)

R Dominguez;DR Morgan;R Sexton;A Rollan;E Pena;ER Greenberg;WD Chey Gastroenterology Vol. 142, Issue 5, Supplement 1, p. S-465, abst. SU1618; Digestive Disease Week Annual Meeting, poster presenation;

Risk factors for Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)

C Porras;J Nodora;R Sexton;R Dominguez;S Jimenez;GL Anderson;R Herrero;LH Baker;ER Greenberg Gastroenterology Vol. 142, Issue 5, Suppl 1, p. S-480; Digestive Disease Week Annual Meeting, poster;

Estimated one-year effectiveness and costs of six H. pylori test-and-treat strategies involving triple, concomitant or sequential drug regimens used with or without follow-up urea breath testing and rescue therapy in seven Latin American sites (SWOG trial S0701)

J Torres;DR Morgan;ER Greenberg;E Salazar-Martinez;R Dominguez;C Ferreccio;LE Bravo;R Pena;R Herrero;M Martinez;P Correa;M Valdivieso;GL Anderson;WD Chey;JJ Crowley;LH Baker Gastroenterology Vol. 142,Issue 5, Suppl 1, p. S-115-S-116; Digestive Disease Week Annual Meeting, oral;

Predictors of success of Helicobacter pylori eradication treatment in a multicentric randomized clinical trial (SWOG S0701)in Latin America

R Herrero;E Salazar-Martinez;R Sexton;DR Morgan;R Dominguez;J Torres;C Ferreccio;LE Bravo;R Pena;M Martinez;P Correa;M Valdivieso;M Meza-Montenegro;GL Anderson;WD Chey;ER Greenberg;JJ Crowley;LH Baker Gastroenterology Vol. 142, Issue 5, Supplement 1, Pages S-183-S-184, 2012; Digestive Disease Week Annual Meeting, oral presentation;

SWOG S0701 phase III randomized trial of three antibiotic regimens to eradicate Helicobacter pylori: efficacy and failure at one-year

LH Baker;JJ Crowley;M Valdivieso;R Dominguez;L Bravo;R Pena;M Meza-Montenegro;P Correa;W Chey;D Morgan;F Meyskens;G Goodman Amercan Association of Cancer Research Annual Meeting, oral presentation (plenary); presentation # SY26-02;

Treatment of Helicobacter pylori in Latin America [correspondence; authors' reply]

ER Greenberg;GL Anderson;DR Morgan;J Torres;W Chey Lancet 379:408-409

PMid: PMID21777974 | PMC number: PMC3313469

2011

A randomized trial comparing 14-day triple, 10-day sequential, and 5-day concomitant therapy to eradicate Helicobacter pylori in seven Latin American populations

C Ferreccio;G Anderson;D Morgan;J Torres;LE Bravo;R Dominguez;R Herrero;M Meza-Montenegro;R Pena;E Salazar-Martinez;W Chey;M Valdivieso;J Crowley;G Goodman;ER Greenberg;LH Baker Digestive Disease Week 2011 meeting, oral presentation

14-day triple, 5-day concomitant, and 10-day sequential therapies for helicobacter pylori infection in seven Latin American sites: a randomised trial [PMID:21777974;PMC3313469]

ER Greenberg;GL Anderson;DR Morgan;J Torres;WD Chey;LE Bravo;RL Dominguez;C Ferreccio;R Herrero;EC Lazcano-Ponce;M Meza-Montenegro;R Pena;E Salazar-Martinez;P Correa;ME Martinez;M Valdivieso;GE Goodman;J Crowley;LH Baker Lancet 378(9790):507-514;

Other Clinical Trials

SWOG Clinical Trial Number
S1823

A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors

Research Committee(s)
Prevention & Epidemiology
Genitourinary Cancer
Activated
06/01/2020
Accrual
99%
Open
Phase
SWOG Clinical Trial Number
CTSU/NHLBI-MDS

The National Myelodysplastic Syndromes (MDS) Study

Research Committee(s)
Prevention & Epidemiology
Leukemia
Activated
06/01/2019
Open
Phase